A SynNotch-PiggyBac gene circuit for inflammation-responsive IL-10 delivery in Alzheimer’s disease: a hypothesis and design framework

Chronic neuroinflammation driven by sustained microglial and astrocyte activation contributes to Alzheimer’s disease progression, yet no therapeutic strategy addresses it with precision or durability in the brain. Interleukin-10 occupies an unresolved position in this problem. Constitutive interleukin-10 overexpression in amyloid precursor protein transgenic mice increased plaque burden by suppressing microglial phagocytic activity, while interleukin-10 deletion has been reported to restrict amyloidosis in one setting and to worsen tau hyperphosphorylation in another. We interpret this pattern as evidence that interleukin-10 carries opposite signs on the two principal pathologies of Alzheimer’s disease, so that any therapy holding it at a fixed concentration is committed in advance to being wrong about one of them. We therefore propose a falsifiable hypothesis: conditional, inflammation-gated interleukin-10 expression may suppress damaging inflammatory signaling while limiting the impairment of microglial phagocytosis associated with continuous exposure. We present a design framework for a synthetic gene circuit combining an adeno-associated viral vector for delivery to the central nervous system, a synthetic Notch receptor that detects membrane-bound tumor necrosis factor alpha on activated microglia through juxtacrine contact, and a PiggyBac transposon intended to integrate the circuit into the astrocyte genome. Receptor engagement is expected to release a transcription factor that drives interleukin-10 from a synthetic promoter, with transcription ceasing as the stimulus is withdrawn. We provide a quantitative packaging analysis showing that the circuit requires a compacted vector design to fit within viral capacity, and we identify three unvalidated assumptions: the recognition domain does not yet exist, ligand surface density on activated microglia is unmeasured, and shed soluble tumor necrosis factor alpha is predicted to act as a competitive inhibitor of receptor activation. A computational analysis of simulated resting-state electroencephalography, in which 45 of 171 electrode pairs differed after false discovery rate correction, is presented as a fully specified analysis workflow for delta-band connectivity as a secondary outcome measure rather than as evidence of effect, and yields effect sizes indicating that a rodent study would need roughly 11 animals per group. A four-arm validation plan is specified that separates the contribution of conditional regulation from that of genomic integration.